Skip to main content

Second-Generation Antihistamines in Asthma Therapy

Is There a Protective Effect?

American Journal of Respiratory Medicine volume 1, pages 27–34 (2002)Cite this article

Abstract

Second-generation histamine H1 receptor antagonists are recognized as being highly effective treatments for allergic-based disease and are among the most frequently prescribed drugs in the world. The newer antihistamines represent a heterogeneous group of compounds with markedly different chemical structures, a spectrum of antihistaminic properties, adverse effects, half-life, tissue distribution, metabolism and varying degrees of anti-inflammatory effects. Histamine is an important mast cell- and basophil-derived mediator that has been implicated in the pathogenesis of asthma, resulting in smooth muscle contraction, mucus hypersecretion, and increased vascular permeability leading to mucosal edema. Antihistamines should never be used as monotherapy for asthma but there is evidence that these drugs give a measure of protection in histamine-induced bronchoconstriction. Furthermore, several studies have demonstrated that the use of second-generation antihistamines, as adjunct therapy, may benefit those patients whose allergic asthma co-exists with allergic rhinitis. Indeed, many patients present with both allergic rhinitis and asthma. The link between the upper and lower respiratory airways is now well established and there is increasing evidence that allergic rhinitis is a risk factor for the development of asthma. More recently, a number of novel antihistamines have been developed which are either metabolites of active drugs or enantiomers and there is emerging evidence that at least one of these drugs, desloratadine, may give significant symptomatic benefit in some types of asthma. It is of interest to note that cetirizine provides a primary pharmacological intervention strategy to prevent the development of asthma in specifically-sensitized high risk groups of infants. Moreover, the documented anti-inflammatory activities of antihistamines may provide a novel mechanism of action for the therapeutic control of virus-induced asthma exacerbations by inhibiting the expression of intercellular adhesion molecule-1 (ICAM-1) by airway epithelial cells. Finally, several well-conducted studies suggest that combination therapy with antihistamines and anti-leukotrienes may be as effective as corticosteroid use in patients with allergic asthma and seasonal allergic rhinitis.

This is a preview of subscription content, access via your institution.

Table I

References

  1. Evans R. Epidemiology and natural history of asthma, allergic rhinitis and atopic dermatitis. In: Middleton Jr E, Reed CE, Ellis EF, editors. Allergy principles and practice. 4th ed. St Louis (MO): Mosby, 1993: 1109–36

    Google Scholar 

  2. Simons FER, Simons KJ. Pharmacokinetic optimisation of histamine H1-receptor antagonist therapy. Clin Pharmokinet 1991; 21: 372–93

    Article  CAS  Google Scholar 

  3. Lipworth BJ. Modern drug treatment of chronic asthma. BMJ 1999; 318: 380–4

    PubMed  Article  CAS  Google Scholar 

  4. Eggleston PA. Upper airway inflammatory diseases and bronchial hyperresponsiveness. J Allergy Clin Immunol 1988; 81: 1036–41

    PubMed  Article  CAS  Google Scholar 

  5. Holgate ST, Finnerty JP. Antihistamines in asthma. J Allergy Clin Immunol 1989; 83: 537–47

    PubMed  Article  CAS  Google Scholar 

  6. Meltzer EO. To use or not to use antihistamines in patients with asthma [editorial]. Ann Allergy 1990; 64: 183–6

    PubMed  CAS  Google Scholar 

  7. Akagi K, Townley RG. Spontaneous histamine-release and histamine content in normal subjects and subjects with asthma. J Allergy Clin Immunol 1989; 83: 742–9

    PubMed  Article  CAS  Google Scholar 

  8. Casale TB, Wood D, Richerson HB. Direct evidence of a role for mast cells in pathogenesis of antigen-induced bronchoconstriction. J Clin Invest 1987; 80: 1507–11

    PubMed  Article  CAS  Google Scholar 

  9. Casale TB, Wood D, Richerson HB. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. J Clin Invest 1987; 79: 1197–203

    PubMed  Article  CAS  Google Scholar 

  10. Malick A, Grant J. Antihistamines in the treatment of asthma. Allergy 1997; 52Suppl. 34: 55–66

    PubMed  Article  CAS  Google Scholar 

  11. Walsh GM, Annunziato L, Frossard N, et al. New insights into the second generation antihistamines. Drugs 2001; 61: 207–36

    PubMed  Article  CAS  Google Scholar 

  12. Church MK. H1 antihistamines and inflammation [editorial]. Clin Exp Allergy 2001; 31: 1341–3

    PubMed  Article  CAS  Google Scholar 

  13. Hayashi S, Hashimoto S. Anti-inflammatory actions of new antihistamines. Clin Exp Allergy 1999; 29: 1593–6

    PubMed  Article  CAS  Google Scholar 

  14. Wood-Baker R, Holgate ST. The comparative actions and adverse effect profile of single doses of H1-receptor antihistamines in the airways and skin of subjects with asthma. J Allergy Clin Immunol 1993; 91: 1005–14

    PubMed  Article  CAS  Google Scholar 

  15. Wood-Baker R, Holgate ST. Dose-response relationship of the H1-histamine antagonist, ebastine, against histamine- and methacholine-induced bronchoconstriction in patients with asthma. Agents Actions 1990 Apr; 30(1–2): 284–6

    PubMed  Article  CAS  Google Scholar 

  16. Chyrek-Borowska S, Siergiejko Z, Michalska I. The effects of a new generation of H1 antihistamines (cetirizine and loratadine) on histamine release and the bronchial response to histamine in atopic patients. J Investig Allergol Clin Immunol 1995; 5(2): 103–7

    PubMed  CAS  Google Scholar 

  17. Ghosh SK, Rafferty P, De Vos C, et al. Effect of cetirizine, a potent H1 antagonist, on platelet activating factor induced bronchoconstriction in asthma. Clin Exp Allergy 1993; 23: 524–7

    PubMed  Article  CAS  Google Scholar 

  18. Busse WW, Middleton E, Storms W, et al. Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Am J Respir Crit Care Med 1996; 153: 122–7

    PubMed  CAS  Google Scholar 

  19. Chervinsky P, Grossman J, Freitag JJ. Duration of action of a single dose of azelastine in patients with chronic asthma. J Asthma 1995; 32: 141–5

    PubMed  Article  CAS  Google Scholar 

  20. An evaluation of the efficacy and safety of azelastine in patients with chronic asthma. Azelastine-Asthma Study Group. J Allergy Clin Immunol 1996; 97: 1218–24

  21. Walsh GM. Advances in the immunobiology of eosinophils and theirrole in disease. Crit Rev Clin Lab Sci 1999; 36: 453–96

    PubMed  Article  CAS  Google Scholar 

  22. Umetsu DT, DeKruyff RH. Th1 and Th2 CD4+ cells in human allergic diseases. J Allergy Clin Immunol 1997; 100: 1–6

    PubMed  Article  CAS  Google Scholar 

  23. Hoshino M, Nakamura Y. The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma. Int Arch Allergy Immunol 1997; 114: 285–92

    PubMed  Article  CAS  Google Scholar 

  24. Wasserfallen JB, Leuenberger P, Pecoud A. Effect of cetirizine, a new H1 antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen. J Allergy Clin Immunol 1993; 91: 1189–97

    PubMed  Article  CAS  Google Scholar 

  25. Bentley AM, Walker S, Hanotte F, et al. A comparison of the effects of oral cetirizine and inhaled beclomethasone on the early and late asthmatic responses to allergen and the associated increases in airways responsiveness. Clin Exp Allergy 1996; 26: 909–17

    PubMed  Article  CAS  Google Scholar 

  26. Bruttmann G, Pedrali P, Arendt C, et al. Protective effect of cetirizine in patients suffering from pollen asthma. Ann Allergy 1990; 64: 224–8

    PubMed  CAS  Google Scholar 

  27. Bousquet J, Emonot A, Germouty J, et al. Double-blind multicenter study of cetirizine in grass pollen-induced asthma. Ann Allergy 1990; 65: 504–58

    PubMed  CAS  Google Scholar 

  28. Dijkman JH, Hekking PR, Molkenboer JF, et al. Prophylactic treatment of grass pollen-induced asthma with cetirizine. Clin Exp Allergy 1990; 20: 483–90

    PubMed  Article  CAS  Google Scholar 

  29. Rafferty P, Ghosh SK, de Vos C, et al. Effect of oral and inhaled cetirizine in allergen-induced bronchoconstriction. Clin Exp Allergy 1993; 23: 528–31

    PubMed  Article  CAS  Google Scholar 

  30. Kopferschmitt-Kubler MC, Couchot A, Pauli G. Evaluation of the effect of oral cetirizine on antigen-induced immediate asthmatic response. Ann Allergy 1990; 65: 501–53

    PubMed  CAS  Google Scholar 

  31. Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomised, placebo controlled trial. J Allergy Clin Immunol 1995; 95: 923–32

    PubMed  Article  CAS  Google Scholar 

  32. Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 1996; 76: 440–6

    PubMed  Article  CAS  Google Scholar 

  33. Spector SL, Nicodemus CF, Corren J, et al. Comparison of the bronchodilatory effects of cetirizine, albuterol and both together versus placebo in patients with mild to moderate asthma. J Allergy Clin Immunol 1995; 96: 174–81

    PubMed  Article  CAS  Google Scholar 

  34. Kjellman NI. Is there a place for antihistamines in the treatment of perennial asthma? Pediatr Allergy Immunol 1993; 4Suppl. 4: 38–43

    PubMed  CAS  Google Scholar 

  35. Aubier M, Neukirch C, Peiffer C, et al. Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergie rhinitis and asthma. Allergy 2001; 56: 35–42

    PubMed  Article  CAS  Google Scholar 

  36. Kroll VM, Nothofer B, Werdermann K. Allergic bronchial asthma treated with loratadine. Fortschr Med 1993; 111: 76–8

    PubMed  CAS  Google Scholar 

  37. Dirksen A, Engel T, Frolund L, et al. Effect of a non-sedative antihistamine (loratadine) in moderate asthma. A double-blind, controlled clinical crossover trial. Allergy 1989; 44: 566–71

    PubMed  Article  CAS  Google Scholar 

  38. Ekstrom T, Osterman K, Zetterstrom O. Lack of effect of loratadine on moderate to severe asthma. Ann Allergy Asthma Immunol 1995; 75(3): 287–98

    PubMed  CAS  Google Scholar 

  39. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100: 781–8

    PubMed  Article  CAS  Google Scholar 

  40. Rafferty P, Jackson L, Smith R, et al. Terfenadine, a potent antihistamine H1-receptor antagonist in the treatment of grass pollen-sensitive asthma. Br J Pharmacol 1990; 30: 229–35

    Article  CAS  Google Scholar 

  41. Taytard A, Beaumont D, Pujet JC, et al. Treatment of bronchial asthma with terfenadine; a randomised controlled trial. Br J Pharmacol 1987; 24: 743–6

    Article  CAS  Google Scholar 

  42. Simons FER, Kesselman MS, Giddins NG, et al. Astemizole-induced torsade de pointes [letter]. Lancet 1988; II(8611): 624

    Article  Google Scholar 

  43. Davies AJ, Harinda V, McEwan A, et al. Cardiotoxic effect with convulsions in terfenadine overdose [letter]. BMJ 1989; 298: 325

    PubMed  Article  CAS  Google Scholar 

  44. Honig P, Baraniuk JN. Adverse effects of H1-receptor antagonists in the cardiovascular system. In: Simons FER, editor. Histamine and H1-receptor antagonists in allergic disease. New York: Marcel Dekker Inc., 1996: 383–412

    Google Scholar 

  45. Horiguchi T, Tachikawa S, Kasahara J, et al. Effect of ebastine on serum eosinophil cationic protein levels in patients with bronchial asthma. Clin Drug Invest 1999; 17: 435–40

    Article  CAS  Google Scholar 

  46. Mygind N, Dahl R, editors. The nose and the paranasal sinuses in asthma. Allergy 1999; 54Suppl. 57: 14–25

    Google Scholar 

  47. Leurs R, Smit MJ, Timmerman H. Molecular pharmacological aspects of histamine receptors. Pharmacol Ther 1995; 66: 413–63

    PubMed  Article  CAS  Google Scholar 

  48. Markham A, Wagstaff AJ. Fexofenadine. Drugs 1998; 55: 269–74

    PubMed  Article  CAS  Google Scholar 

  49. McCellan K, Jarvis B. Desloratadine. Drugs 2001; 61: 789–96

    Article  Google Scholar 

  50. Devalia JL, De Vos C, Hanotte F, et al. A randomised double-blind crossover comparison among cetirizine, levocetirizine and UCB 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001; 56: 50–7

    PubMed  Article  CAS  Google Scholar 

  51. Wang DY, Hanotte F, De Vos C, et al. Effect of cetirizne, levocetirizine and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy 2001; 56: 339–43

    PubMed  Article  CAS  Google Scholar 

  52. Brannan JD, Anderson SD, Gomes K, et al. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med 2001; 163: 1420–5

    PubMed  CAS  Google Scholar 

  53. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal seasonal allergic rhinitis and asthma. Allergy 2001; 56Suppl. 65: 21–7

    PubMed  Google Scholar 

  54. Schroeder JT, Schleimer RP, Lichtenstein LM, et al. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001; 31: 1369–77

    PubMed  Article  CAS  Google Scholar 

  55. Volovitz B, Varsano I, Cumella JC, et al. Efficacy and safetey of ketotifen in young children with asthma. J Allergy Clin Immunol 1988; 81: 526–30

    PubMed  Article  CAS  Google Scholar 

  56. Kjellman NIM. Is there a place for antihistamines in the treatment of perennial asthma? Ped Allergy Immunol 1993; 4Suppl. 4: 38–43

    CAS  Google Scholar 

  57. Wahn U, Bergmann R, Kulig M, et al. The natural course of sensitisation and atopic disease in infancy and childhood. Pediatr Allergy Immunol 1997; 8(10 Suppl.): 16–20

    PubMed  CAS  Google Scholar 

  58. Iikura Y, Naspitz CK, Mikawa H. Prevention of asthma by ketotifen in infants with atopic dermatits. Ann Allergy 1992; 68: 233–6

    PubMed  CAS  Google Scholar 

  59. Passalacqua G, Bousquet J, Bachert C, et al. The clinical safety of H1-receptor antagonists. An EAACI position paper. Allergy 1996; 51: 666–75

    PubMed  CAS  Google Scholar 

  60. ETAC Study Group. Allergic factors associated with the development of asthma and the influence of cetirizine on this progression in a double-blind, randomised, placebo-controlled trial: first results of ETAC. Pediatr Allergy Immunol 1998; 9: 116–24

    Article  Google Scholar 

  61. Simons FER. Prospective long term safety evaluation of the H1-receptor antagonist cetirizine in very young children with atopic dermatitis. J Allergy Clin Immunol 1999; 104: 433–40

    PubMed  Article  CAS  Google Scholar 

  62. Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor intracellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription. J Biol Chem 1999; 274: 9707–20

    PubMed  Article  CAS  Google Scholar 

  63. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clin Immunol 1995; 95: 612–21

    PubMed  Article  CAS  Google Scholar 

  64. Ciprandi G, Buscaglia S, Pronzato C, et al. Oxatomide reduces inflammatory events induced by allergen-specific conjunctival challenge. Ann Allergy 1995; 75: 446–52

    CAS  Google Scholar 

  65. Ciprandi G, Buscaglia S, Marchesi E, et al. Protective effect of loratadine on late phase reaction induced by conjunctival provocation test. Int Arch Allergy Appl Immunol 1994; 100: 185–9

    Article  Google Scholar 

  66. Ciprandi G, Buscaglia S, Iudice A, et al. Protective effect of terfenadine at different dosages on conjunctival provocation test. Allergy 1992; 47: 309–12

    PubMed  Article  CAS  Google Scholar 

  67. Fasce L, Ciprandi G, Pronzato C, et al. Cetirizine reduces ICAM-1 on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int Arch Allergy Immunol 1996; 109: 272–6

    PubMed  Article  CAS  Google Scholar 

  68. Papi A, Nikolaos G, Papadopoulos NG, et al. Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule-1 upregulation and promoter activation in respiratory epithelial cells. J Allergy Clin Immunol 2001; 108: 221–8

    PubMed  Article  CAS  Google Scholar 

  69. Arnold R, Rihoux JP, Konig W. Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549). Clin Exp Allergy 1999; 29: 1681–91

    PubMed  Article  CAS  Google Scholar 

  70. Doull IJ, Lampe FC, Smith S, et al. Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: radomised double blind placebo contolled trial. BMJ 1997; 315: 858–62

    PubMed  Article  CAS  Google Scholar 

  71. Diamant Z, Sampson AP. Anti-inflammatory effects of leukotriene modulators. Clin Exp Allergy 1999; 29(11): 1449–53

    PubMed  Article  CAS  Google Scholar 

  72. Lipworth BJ. Leukotriene receptor antagonists. Lancet 1999; 353: 57–62

    PubMed  Article  CAS  Google Scholar 

  73. Reicin A, White R, Weinstein SF, et al. Montelukast, a leukotriene receptor antagonist, in combination with loratadine, a histamine receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 2000; 160: 2481–8

    PubMed  Article  CAS  Google Scholar 

  74. Roquet A, Dahen B, Kumlin M. Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Resp Crit Care Med 1997; 155:1856–63

    PubMed  CAS  Google Scholar 

  75. Wilson AM, Orr LC, Sims EJ, et al. Antiasthmatic effects of mediator blockade versus topical crticosteroids in allergic rhinitis and asthma. Am J Resp Crit Care Med 2000; 162: 1297–301

    PubMed  CAS  Google Scholar 

  76. Wilson AM, Orr LC, Sims EJ, et al. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonist in seaonal allergic rhinitis. Clin Exp Allergy 2000; 31: 61–8

    Google Scholar 

Download references

Acknowledgements

The author wishes to acknowledge the following bodies who fund his research: The Chief Scientists Office (Scottish Executive); The Leverhulme Trust; UCB Pharma SA, Scottish Hospitals Endowment Research Trust, and Merck, Sharp and Dohme Ltd.

Author information

Affiliations

  1. Department of Medicine & Therapeutics, University of Aberdeen Medical School, IMS Building, Foresterhill, Aberdeen, AB25 2ZD, UK

    Garry M. Walsh

Authors
  1. Garry M. Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Garry M. Walsh.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Walsh, G.M. Second-Generation Antihistamines in Asthma Therapy. Am J Respir Med 1, 27–34 (2002). https://doi.org/10.1007/BF03257160

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03257160

Keywords

  • Asthma
  • Atopic Dermatitis
  • Allergic Rhinitis
  • Montelukast
  • Terfenadine